Home

•  
  • Governance
    • Board of Directors
    • Bylaws
    • Policy Handbook
    • Strategic Planning
  • Subscribe to the ASFA Newsflash
•  
  • Disease & Treatment
    • Fact Sheets
  • Glossary
•  
  • Membership
    • Join ASFA
    • Membership Renewal
    • Corporate Membership
    • Update Your Membership Profile
    • Membership Directory
    • Facility Directory
  • Related Links
  • Journal of Clinical Apheresis
  • ASFA Guidelines
  • Apheresis Reimbursement
  • Educational Materials
  • Corporate Resources
  • ASFA Webinars
    • 2012 Webinar Schedule
  • Annual Meeting
    • Registration
    • Accommodation
    • Transportation
    • Continuing Education Credit
    • Corporate Support and Exhibiting
    • ASFA 2011 Annual Meeting Presentations
    • ASFA 2012 TTP Consensus Conference
    • ASFA Annual Meeting Photos
    • Workshop and Symposia Information
    • Future ASFA Annual Meetings
    • ASFA 2012 Preliminary Program
    • Atlanta Tourism
    • ASFA Awards
  • Regional Meeting
  • Research
  • Careers in Apheresis
  • Committees
    • Abstracts Committee
    • Allied Health Committee
    • Apheresis Applications Committee
    • Awards Committee
    • Bylaws Committee
    • Certification Committee
    • Communications Committee
    • Education Committee
    • History and Archives Committee
    • International Affairs Committee
    • Membership Committee
    • Nominations Committee
    • Public Affairs and Advocacy Committee
    • Apheresis Physicians Committee
  • Discussion Forum
•  

For Apheresis Professionals   |    Corporate Resources

Corporate Resources

Therapeutic Plasma Exchange (TPE) and Intravenous Immunoglobulin (IVIG)

Refer to the following article that addresses a cost minimization analysis of the direct costs of TPE and IVIG treatments.

http://www.biomedcentral.com/1472-6963/11/101

Given equivalent efficacy and similar severity and frequencies of adverse events, TPE appears to be a less expensive first-line therapy option. For additional information regarding the cost model addressed in this article please contact Ashok Chainani at Ashok.Chainani@CaridianBCT.com.

---

Growing Your TPE/PLEX Business – The Value Proposition

Download and watch this free presentation today! This resource is a live recording of a presentation delivered by Ashok Chainani of CardianBCT demonstrating best practices and offering free resources for growing your TPE/PLEX business.

Title: Growing Your TPE/PLEX Business – The Value Proposition
Presenter: Ashok Chainani, CaridianBCT
.
Presentation Objectives:

1. Learn about cost differences between two different treatment regimens – Therapeutic Plasma Exchange (TPE/PLEX) and IVIG.
2. Leverage the knowledge to inform physicians of the TPE/PLEX option.
3. Key take-away: In the outpatient setting, TPE/PLEX offers significant savings while providing comparable¹ health outcomes
   
   

Source: ¹ Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Lancet 1997;349:225-230. to download this presentation now. Please note you will need quicktime or iTunes to view this file

Click Here to Download this Presentation Now. (Please note: This file is in MP4 format and you will need Quicktime or iTunes to view this presentation)